InStatin to Study Inhalable Statin for Asthma and COPD Treatment

Key Insights

• InStatin will conduct a non-GLP discovery study with Mountain West Research to assess the pharmacokinetics of its statin inhalant solution.
• The study aims to optimize the targeted delivery of the active pharmaceutical ingredient (API) to the lungs, enhancing efficacy and bioavailability.
• The research findings will guide the development of InStatin's respiratory solutions, in preparation for Phase 1 human trials.

InStatin, a strategic investment portfolio company of Therma Bright Inc., has entered into an agreement with Mountain West Research to conduct a non-GLP discovery study. This research will investigate the pharmacokinetics of InStatin's innovative statin inhalant solution, focusing on the behavior of the active pharmaceutical ingredient (API) in both lung and systemic blood circulation.

The study is designed to provide insights into how to effectively target the delivery of the solution's API within the lungs. By clarifying the optimal delivery method, InStatin aims to enhance the efficacy, bioavailability, and overall treatment outcomes for patients with asthma and chronic obstructive pulmonary disease (COPD).

Optimizing Lung Delivery for Respiratory Solutions

The pre-clinical research will play a crucial role in guiding the next phases of InStatin's product development. The company anticipates that the results will be instrumental in preparing for Phase 1 human trials, marking a significant step forward in the development of novel respiratory therapies.

Rob Fia, CEO of Therma Bright, emphasized the importance of this research, stating, "The research efforts between InStatin and Mountain West Research underscores our investment portfolio company's commitment to our vision of 'Transforming Innovation into Wellness' with the pursuit of developing effective asthma and COPD treatments." He added, "We are confident that the findings from this study will validate the potential of innovative lung delivery systems and their positive impact on patient health."

Market Growth in Asthma Treatment

According to a Nova1Advisor's report highlighted in a BioSpace article, the Asthma Treatment market is projected to reach USD 39.04 billion by 2032, exhibiting a CAGR of 3.8% from 2023 to 2032. This growth underscores the increasing demand for effective asthma and COPD treatments, an area in which InStatin seeks to make a significant contribution.

Therma Bright currently holds a 17% stake in InStatin, with potential for increased ownership through future financing rounds.